Approved for use through 07731/21.COM 06151/0312

U.S. Patent and Trackmark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless of slightlys a valid OMB control number. STATEMENT UNDER 37 CFR 3,73(b)

Applicant/Patent Owner: Arriva Pharmaceuticals, Inc.	
	Filed/issue Date: August 26, 2006
Titled:	Tiledrissde Date. Tiligast 25, 2000
Dry Recombinant Human Alpha 1-Antitrypsin Formulation	
Arriva Pharmaceuticals, Inc. , a	Corporation
(Name of Assignee)	(Type of Assignce, e.g., corporation, partnership, university, government agency, etc.
states that it is:	
1.  the assignee of the entire right, title, and interest in;	
2. an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is%); or	
3.	
the patent application/patent identified above, by virtue of either:	
A. X an assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 021219 Frame 0718 or for which a copy therefore is attached.	
OR	
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:	
1. From:	To:
The document was recorded in the United States Patent and Trademark Office at	
Reel, Fran	ne, or for which a copy thereof is attached.
2. From:	То:
The document was recorded in the United States Patent and Trademark Office at	
Reel, Fram	ne, or for which a copy thereof is attached.
3. From:	To:
The document was recorded in the Ur	nited States Patent and Trademark Office at
Reel, Fram	ne, or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet(s).	
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.	
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]	
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.	
/Jeffery P. Bernhardt/	February 8, 2010
Signature	Date
Jeffery P. Bernhardt	Attorney, Reg. No. 54,997
Printed or Typed Name	Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confedentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to compete, including experiment, proprient, and schemiting the completed applications from the USPTO. Time will vary deposing upon the individual case. Any commission of the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tracematic Officer, Department of Commerce, P.O. Both 1500, Accessariate, N. 2 ST31-1450. D. OND TESSOP ESSOP ESSOR ES for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,